1. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206–1252. [PubMed] [Google Scholar]
2. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population: results from the 3rd National Health and Nutrition Examination Survey, 1988–1991. Hypertension. 1995;25(3):305–313. [PubMed] [Google Scholar]
3. Yusuf PS, Hawken S, Ôunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. The Lancet. 2004;364(9438):937–952. [PubMed] [Google Scholar]
4. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. The Lancet. 2002;360(9349):1903–1913. [PubMed] [Google Scholar]
5. Whelton PK, He J, Muntner P. Prevelance, awareness, treatment and control of hypertension in North America, North Africa and Asia. Journal of Human Hypertension. 2004;18(8):545–551. [PubMed] [Google Scholar]
6. American Heart Association. Heart Disease and Stroke Statistics-2007 Update. Dallas, Tex, USA: American Heart Association; 2007. [Google Scholar]
7. Murray CJ, Lopez AD. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020. Vol. 1. Cambridge, Mass, USA: Harvard School of Public Health; 1996. (Global Burden of Disease and Injury Series). [Google Scholar]
8. Ôunpuu S, Negassa A, Yusuf S. INTER-HEART: a global study of risk factors for acute myocardial infarction. American Heart Journal. 2001;141(5):711–721. [PubMed] [Google Scholar]
9. Okrainec K, Banerjee DK, Eisenberg MJ. Coronary artery disease in the developing world. American Heart Journal. 2004;148(1):7–15. [PubMed] [Google Scholar]
10. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association council for high blood pressure research and the councils on clinical cardiology and epidemiology and prevention. Circulation. 2007;115(21):2761–2788. [PubMed] [Google Scholar]
11. Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. Annals of Internal Medicine. 2003;139(9):761–776. [PubMed] [Google Scholar]
12. Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. Journal of Hypertension. 2005;23(1, supplement):S9–S17. [PubMed] [Google Scholar]
13. Levy D, Anderson KM, Savage DD, Kannel WB, Christiansen JC, Castelli WP. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham heart study. Annals of Internal Medicine. 1988;108(1):7–13. [PubMed] [Google Scholar]
14. Rheeder P, Stolk RP, Mosterd A, Pols HAP, Hofman A, Grobbee DE. Insulin resistance syndrome and left ventricular mass in an elderly population (the Rotterdam study) American Journal of Cardiology. 1999;84(2):233–236. [PubMed] [Google Scholar]
15. Frohlich ED. Hypertension, left ventricular hypertrophy, and coronary flow reserve. Advances in Experimental Medicine and Biology. 1997;432:253–262. [PubMed] [Google Scholar]
16. Kannel WB, Wilson PWF. Cardiovascular risk factors and hypertension. In: Izzo JL Jr., Black HR, editors. Hypertension Primer. 3rd edition. Dallas, Tex, USA: American Heart Association; 2003. pp. 235–238. [Google Scholar]
17. Vaitkevicius PV, Fleg JL, Engel JH, et al. Effects of age and aerobic capacity on arterial stiffness in healthy adults. Circulation. 1993;88(4):1456–1462. [PubMed] [Google Scholar]
18. McGuire KA, Janssen I, Ross R. Ability of physical activity to predict cardiovascular disease beyond commonly evaluated cardiometabolic risk factors. American Journal of Cardiology. 2009;104(11):1522–1526. [PubMed] [Google Scholar]
19. Hambrecht R, Wolf A, Gielen S, et al. Effect of exercise on coronary endothelial function in patients with coronary artery disease. New England Journal of Medicine. 2000;342(7):454–460. [PubMed] [Google Scholar]
20. Bauman AE. Updating the evidence that physical activity is good for health: an epidemiological review 2000–2003. Journal of Science and Medicine in Sport. 2004;7(1):6–19. [PubMed] [Google Scholar]
21. Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation. 1999;99(16):2192–2217. [PubMed] [Google Scholar]
22. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: executive summary: a report of the ACC/AHA Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction) Circulation. 2004;110:588–636. [PubMed] [Google Scholar]
23. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: executive summary: a report of the ACC/AHA Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction) Circulation. 2005;111:p. 2013. [PubMed] [Google Scholar]
24. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina—summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina) Journal of the American College of Cardiology. 2003;41(1):159–168. [PubMed] [Google Scholar]
25. Wang JG, Staessen JA. Benefits of antihypertensive pharmacologic therapy and blood pressure reduction in outcome trials. Journal of Clinical Hypertension. 2003;5(1):66–75. [PMC free article] [PubMed] [Google Scholar]
26. Viskin S, Kitzis I, Lev E, et al. Treatment with beta-adrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice. Journal of the American College of Cardiology. 1995;25(6):1327–1332. [PubMed] [Google Scholar]
27. Goldstein S. β-Blockers in hypertensive and coronary heart disease. Archives of Internal Medicine. 1996;156(12):1267–1276. [PubMed] [Google Scholar]
28. Frishman WH, Cheng A. Secondary prevention of myocardial infarction: role of β–adrenegic blockers and angiostein converting enzyme inhibitors. American Heart Journal. 1999;137:S25–S34. [PubMed] [Google Scholar]
29. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. The Lancet. 2005;366(9489):895–906. [PubMed] [Google Scholar]
30. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFÉ) study. Circulation. 2006;113(9):1213–1225. [PubMed] [Google Scholar]
31. Olafiranye O, Qureshi G, Salciccioli L, Weber M, Lazar JM. Association of beta-blocker use with increased aortic wave reflection. Journal of the American Society of Hypertension. 2008;2(2):64–69. [PubMed] [Google Scholar]
32. Rosendorff C. Calcium antagonists in the treatment of hypertension in patients with ischaemic heart disease. Expert Opinion on Pharmacotherapy. 2003;4(9):1535–1541. [PubMed] [Google Scholar]
33. Black HR, Elliott WJ, Grandits G, et al. Principal results of the controlled onset verapamil investigation of cardiovascular end points (CONVINCE) trial. Journal of the American Medical Association. 2003;289(16):2073–2082. [PubMed] [Google Scholar]
34. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. The Lancet. 2000;356(9227):359–365. [PubMed] [Google Scholar]
35. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease the international verapamil-trandolapril study (INVEST): a randomized controlled trial. Journal of the American Medical Association. 2003;290(21):2805–2816. [PubMed] [Google Scholar]
36. Goldstein RE, Boccuzzi SJ, Cruess D, et al. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation. 1991;83:52–60. [PubMed] [Google Scholar]
37. ALLHAT-Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Journal of the American Medical Association. 2002;288:2981–2997. [PubMed] [Google Scholar]
38. ALLHAT-Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Journal of the American Medical Association. 2003;289:p. 178. [PubMed] [Google Scholar]
39. ALLHAT-Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Journal of the American Medical Association. 2004;291:p. 2196. [PubMed] [Google Scholar]
40. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. The Lancet. 2004;363(9426):2022–2031. [PubMed] [Google Scholar]
41. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112:e154–e235. [PubMed] [Google Scholar]
42. Alderman MH, Cohen H, Roqué R, Madhavan S. Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients. The Lancet. 1997;349(9052):594–598. [PubMed] [Google Scholar]
43. Hennekens CH, Albert CM, Godfried SL, Gaziano JM, Buring JE. Drug therapy: adjunctive drug therapy of acute myocardial infarction—evidence from clinical trials. New England Journal of Medicine. 1996;335(22):1660–1667. [PubMed] [Google Scholar]
44. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. The Lancet. 2003;362(9395):1527–1535. [PubMed] [Google Scholar]
45. Mason RP. Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence. Atherosclerosis. 2002;165(2):191–199. [PubMed] [Google Scholar]
46. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. The Lancet. 1995;345:669–685. [PubMed] [Google Scholar]
47. Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico. GISSI-3: effects of lisinopri1 and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. The Lancet. 1994;343:1115–1122. [PubMed] [Google Scholar]
48. Fox KM, EURopean Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) The Lancet. 2003;362:782–788. [PubMed] [Google Scholar]
49. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation study. New England Journal of Medicine. 2000;342:145–153. [PubMed] [Google Scholar]
50. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation study. New England Journal of Medicine. 2000;342:p. 1376. [PubMed] [Google Scholar]
51. Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension. 2001;38(6):E28–E32. [PubMed] [Google Scholar]
52. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. New England Journal of Medicine. 2004;351(20):2058–2068. [PMC free article] [PubMed] [Google Scholar]
53. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100 000 patients in randomized trials. Circulation. 1998;97(22):2202–2212. [PubMed] [Google Scholar]
54. Flather MD, Yusuf S, Køber L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. The Lancet. 2000;355(9215):1575–1581. [PubMed] [Google Scholar]
55. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. New England Journal of Medicine. 2003;349(20):1893–1906. [PubMed] [Google Scholar]
56. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. New England Journal of Medicine. 2004;350:p. 203. [PubMed] [Google Scholar]
57. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension. 2004;43(5):963–969. [PubMed] [Google Scholar]
58. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP) Journal of the American Medical Association. 1991;265(24):3255–3264. [PubMed] [Google Scholar]
59. Effects of treatment on morbidity in hypertension, II: results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. Journal of the American Medical Association. 1970;213:1143–1152. [PubMed] [Google Scholar]
60. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. British Medical Journal. 1985;291(6488):97–104. [PMC free article] [PubMed] [Google Scholar]
61. Wang JG, Staessen JA. Benefits of antihypertensive pharmacologic therapy and blood pressure reduction in outcome trials. Journal of Clinical Hypertension. 2003;5(1):66–75. [PMC free article] [PubMed] [Google Scholar]
62. Staessen JA, Wang J-G, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. Journal of Hypertension. 2003;21(6):1055–1076. [PubMed] [Google Scholar]